Abstract:Polymer drug conjugates have demonstrated application potentials in optimizing chemotherapeutics. In this study a new bioconjugate, HA-ss-PTX, was designed and synthesized with cooperative dual characteristics of active tumor targeting and selective intracellular drug release. Paclitaxel (PTX) was covalently attached to hyaluronic acid (HA) with various sizes (MW 9.5, 35, 770 kDa); a cross-linker containing disulfide bond was also used to shield drug leakage in blood circulation and to achieve rapid drug release in tumor cells in response to glutathione. Incorporation of HA to the conjugate enhanced the capabilities of drug loading, intracellular endocytosis and tumor targeting of micelles in comparison to mPEG. HA molecular weight showed significant effect on properties and antitumor efficacy of the synthesized conjugates. Intracellular uptake of HA-ss-PTX toward MCF-7 cells was mediated by CD44-caveolae-mediated endocytosis. Compared to Taxol and mPEG-ss-PTX, HA9.5-ss-PTX demonstrated improved tumor growth inhibition in vivo with a TIR of 83.27 +/- 5.20%. It was concluded that HA9.5-ss-PTX achieved rapid intracellular release of PTX and enhanced its therapeutic efficacy, thus providing a platform for specific drug targeting and controlled intracellular release in chemotherapeutics.Statement of SignificancePolymer drug conjugates, promising nanomedicines, still face some technical challenges including a lack of specific targeting and rapid intracellular drug release at the target site. In this manuscript we designed and constructed a novel bioconjugate HA-ss-PTX, which possessed coordinated dual characteristics of active tumor targeting and selective intracellular drug release. Redox-responsive disulfide bond was introduced to the conjugate to shield drug leakage in blood circulation and to achieve rapid drug release at tumor site in response to reductant like glutathione. Paclitaxel was selected as a model drug to be covalently attached to hyaluronic acid (HA) with various sizes to elucidate the structure activity relationship and to address whether HA could substitute PEG as a carrier for polymeric conjugates. Based on a series of in vitro and in vivo experiments, HA-ss-PTX performed well in drug loading, cellular internalization, tumor targeting by entering tumor cells via CD44-caveolae-mediated endocytosis and rapidly release drug at target in the presence of GSH. One of the key issues in clinical oncology is to enhance drug delivery efficacy while minimizing side effects. The study indicated that this new polymeric conjugate system would be useful in delivering anticancer agents to improve therapeutic efficacy and to minimize adverse effects, thus providing a platform for specific drug targeting and controlled intracellular release in chemotherapeutics. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Redox-sensitive Micelles for Targeted Intracellular Delivery and Combination Chemotherapy of Paclitaxel and All-Trans-retinoid Acid

Redox-Sensitive Micelles Self-Assembled from Amphiphilic Hyaluronic Acid-Deoxycholic Acid Conjugates for Targeted Intracellular Delivery of Paclitaxel

Redox-sensitive Micelles Based on Retinoic Acid Modified Chitosan Conjugate for Intracellular Drug Delivery and Smart Drug Release in Cancer Therapy

Redox-sensitive hyaluronic acid–paclitaxel conjugate micelles with high physical drug loading for efficient tumor therapy

Biological Evaluation of Redox-Sensitive Micelles Based on Hyaluronic Acid-Deoxycholic Acid Conjugates for Tumor-Specific Delivery of Paclitaxel.

Redox-Sensitive Micelles Based on O,N-Hydroxyethyl Chitosan-Octylamine Conjugates for Triggered Intracellular Delivery of Paclitaxel

Prodrug Micelles Based on Norbornene-Functional Poly(lactide)s Backbone for Redox-Responsive Release of Paclitaxel

Intracellular Delivery and Antitumor Effects of a Redox-Responsive Polymeric Paclitaxel Conjugate Based on Hyaluronic Acid.

Redox-sensitive Dimeric Paclitaxel Choline Phosphate Nanoliposomes for Improved Anticancer Efficacy

Reduction-sensitive Mixed Micelles for Selective Intracellular Drug Delivery to Tumor Cells and Reversal of Multidrug Resistance.

Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy

Multifunctional Hyaluronic Acid-Decorated Redox-Responsive Magnetic Complex Micelle for Targeted Drug Delivery with Enhanced Antitumor Efficiency and Anti-Cell-Migration Activity.

Efficient Simultaneous Tumor Targeting Delivery of All-Trans Retinoid Acid and Paclitaxel Based on Hyaluronic Acid-Based Multifunctional Nanocarrier

Redox-responsive micelles from disulfide bond-bridged hyaluronic acid-tocopherol succinate for the treatment of melanoma

Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion

Dehydroascorbic Acids-Modified Polymer Micelles Target Cancer Cells to Enhance Anti-Tumor Efficacy of Paclitaxel

Redox-responsive AIE micelles for intracellular paclitaxel delivery

Redox-sensitive Self-Assembled Nanoparticles Based on Alpha-Tocopherol Succinate-Modified Heparin for Intracellular Delivery of Paclitaxel.

Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer.

Redox-sensitive Micelles Assembled from Amphiphilic Mpeg-Pcl-ss-dtx Conjugates for the Delivery of Docetaxel.

Biotin-modified acid-sensitive micelles for enhancing antitumor effect of paclitaxel